{
    "body": "Are proteasome inhibitors good candidates for treatment of leukemia and solid tumors?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22057347", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17145882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22012631", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15169797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20160034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20219102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19712963", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17431003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19821999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22134540", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23477519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16135477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23181572", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22353937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22995770", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12171876"
    ], 
    "ideal_answer": [
        "Yes, several compounds that inhibit different members of the proteasome pathway (for example Bortezomib) are on trial for treatment of leukemia and solid tumors. It seems that a combination with other drugs may be a useful therapy for solid tumors."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061988", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007938"
    ], 
    "type": "yesno", 
    "id": "517179718ed59a060a00000e", 
    "snippets": [
        {
            "offsetInBeginSection": 824, 
            "offsetInEndSection": 1115, 
            "text": "We show that treatment with b-AP15 inhibited tumor progression in four different in vivo solid tumor models and inhibited organ infiltration in an acute myeloid leukemia model. Our results show that the deubiquitinating activity of the 19S regulatory particle is a new anticancer drug target", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057347", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1126, 
            "offsetInEndSection": 1464, 
            "text": "We further found that ATO targets AME via both myelodysplastic syndrome 1 (MDS1) and EVI1 moieties and degrades EVI1 via the ubiquitin-proteasome pathway and MDS1 in a proteasome-independent manner. Our results suggest that ATO could be used as a part of targeted therapy for AME-, AML1/MDS1-, MDS1/EVI1-, and EVI1-positive human cancers.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145882", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 315, 
            "offsetInEndSection": 795, 
            "text": "Previously we had shown the synergic effect of bortezomib and thiostrepton in breast cancer cells in vitro, where sub-apoptotic concentrations of both proteasome inhibitors resulted in synergic increase in cell death when combined as a treatment. Here, we administered such a combination to MDA-MB-231 xenograft tumors in vivo, and found that the effect of complementary proteasome inhibitors reduced tumor growth rates more efficiently than compared with when administered alone.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22353937", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1477, 
            "offsetInEndSection": 1678, 
            "text": "Addition of a proteasome inhibitor to anti-hormonal therapy resulted in a clinical benefit rate of 22% in a limited number of patients with endocrine resistant and progressive metastatic breast cancer.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134540", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1168, 
            "offsetInEndSection": 1288, 
            "text": "Taken together, these data support the clinical development of MLN9708 for both hematologic and solid tumor indications.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20160034", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1584, 
            "offsetInEndSection": 1690, 
            "text": "Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19712963", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1421, 
            "offsetInEndSection": 1762, 
            "text": "Our study indicates a molecular mechanism by which the sensitivity of thyroid cancer cells is regulated by the level of GRP78 as well as preferential induction of GRP78 or CHOP upon treatment with proteasome inhibitors. Our experiments therefore suggest a novel approach toward sensitization of thyroid cancer cells to proteasome inhibitors.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17431003", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1270, 
            "offsetInEndSection": 1511, 
            "text": "Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week. This dose correlates with 70% inhibition of 20S proteasome activity.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135477", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1459, 
            "offsetInEndSection": 1709, 
            "text": "The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m(2). Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15169797", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1038, 
            "offsetInEndSection": 1278, 
            "text": "Given the results of this trial, it is safe and reasonable to recommend treatment with PS341 on the schedule used in this trial at 1.56 mg/m2/dose in Phase II trials. Particular care should be taken with patients with preexisting neuropathy", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171876", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 518, 
            "offsetInEndSection": 647, 
            "text": "The successes of proteasome inhibitors in MM are now being translated to other hematologic malignancies, including acute leukemia", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477519", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 843, 
            "offsetInEndSection": 1048, 
            "text": "Such efforts have led to bortezomib, the first FDA approved proteasome inhibitor now used as a frontline treatment for newly diagnosed multiple myeloma (MM), relapsed/refractory MM and mantle cell lymphoma", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181572", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 383, 
            "offsetInEndSection": 696, 
            "text": "We recently reported the impact and mechanisms of carfilzomib and oprozomib, second-in-class proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma (HNSCC). Carfilzomib and oprozomib potently inhibit HNSCC cell survival and the growth of HNSCC tumors", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995770", 
            "endSection": "sections.0"
        }
    ]
}